Richard A. Larson to Cell Cycle
This is a "connection" page, showing publications Richard A. Larson has written about Cell Cycle.
Connection Strength
0.118
-
The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes. Leuk Lymphoma. 1994 Jul; 14(3-4):273-8.
Score: 0.027
-
Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients. Blood. 1992 Nov 15; 80(10):2600-3.
Score: 0.024
-
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
Score: 0.020
-
Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B. Cell Immunol. 1983 Oct 15; 81(2):357-72.
Score: 0.013
-
Neutrophils are required for the DNA synthetic response of human lymphocytes to mevalonic acid: evidence suggesting that a nonsterol product of mevalonate is involved. Proc Natl Acad Sci U S A. 1982 May; 79(9):3028-32.
Score: 0.011
-
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. Am J Hematol. 1993 Aug; 43(4):286-90.
Score: 0.006
-
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. Am J Hematol. 1993 Apr; 42(4):359-66.
Score: 0.006
-
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood. 1991 Mar 01; 77(5):1064-70.
Score: 0.005
-
Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients. Leuk Res. 1991; 15(9):773-80.
Score: 0.005